Evidence Snapshot

EL4

CHEMBL614293 CELL-LINE Mus musculus

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:38Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:20 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL614293

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats EL4 as ChEMBL target CHEMBL614293. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

EL4

CELL-LINE · Mus musculus

As of 2026-09-13

ChEMBL target ID

CHEMBL614293

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why EL4 matters

As of 2026-09-13

EL4 is reviewed as EL4; the current evidence base includes 8 approved drugs, 232 compounds, and 41 assays, with lead potency reaching pChEMBL 10.0.

Protein context

EL4

Review this target as EL4.

Protein source · UniProt accession via ChEMBL component mapping

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 232 compounds, and 41 assays for this target. The dominant activity type is IC50. CHEMBL428647 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL428647 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine

8 approved pChEMBL 10.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why EL4 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

232

Total Compounds

Total Assays

Approved Drugs

IC50: 152.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL428647	10.0	IC50	Approved
No preferred name CHEMBL888	8.2	IC50	Approved
No preferred name CHEMBL5269153	7.8	IC50	—
No preferred name CHEMBL4536105	7.6	IC50	—
No preferred name CHEMBL5286627	7.6	IC50	—